^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    birabresib (OTX015)

    i
    Company:
    Merck (MSD)
    Drug class:
    BRD4 inhibitor, BRD2 inhibitor, BRD3 inhibitor
    Related drugs:
    Apply
    A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) (NCT01713582)
    Phase 1
    Oncoethix GmbH
    Completed
    Last update posted :
    01/26/2021
    Initiation :
    12/14/2012
    Primary completion :
    01/20/2017
    Completion :
    01/20/2017
    ABL1 • BCR
    |
    birabresib (OTX015)
    A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) (NCT02259114)
    Phase 1
    Oncoethix GmbH
    Completed
    Last update posted :
    01/26/2021
    Initiation :
    10/23/2014
    Primary completion :
    03/03/2017
    Completion :
    03/03/2017
    KRAS • ALK • NUTM1
    |
    KRAS mutation • ALK rearrangement • ALK fusion
    |
    birabresib (OTX015)